Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. Users share experiences and results with these treatments.

A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

A 31-year-old male shared his 3-year progress using finasteride 1 mg daily, with additional treatments including nutrafol, multivitamins, vitamin D, marine collagen, PRP scalp injections, micro-needling, and Nizoral. He experienced temporary libido issues but currently has no side effects.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The conversation is about finding a source for RU58841 as a substitute for finasteride for hair loss treatment. Suggestions include Amazon and Anageninc.com.

Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.

Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

An experiment to determine the effectiveness of Pyrilutamide in reducing hair loss, using a regimen of Minoxidil and Finasteride, with promising results. The conversation also suggests comparing this to RU58841 as an alternative.

A 20-year-old is experiencing severe diffuse thinning and shedding despite using oral minoxidil for 12 months and dutasteride for 8 months, after previously trying finasteride. They are frustrated with the lack of improvement and considering trying RU58841.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The conversation is about someone's 13-month hair regrowth progress using 0.5 mg Dutasteride daily, 5% Minoxidil twice daily, Biotin tablets, and Sebizole shampoo. They are happy with the results.

A 21-year-old male is experiencing hair thinning and has undergone PRP treatment while considering finasteride but is concerned about its side effects. A user suggests that PRP is ineffective without finasteride and advises against using biotin.

The user has been using finasteride for a year to stop hair loss and is considering adding RU58841 instead of minoxidil to further inhibit DHT. Another user suggests adding dutasteride for better DHT inhibition, but the original user cannot access it and is considering RU58841 despite potential side effects.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.